Evidence map›Paper›PMID 37051060›Full record

ArticleFrontiers in neurology2023

Sustained response in early responders to safinamide in patients with Parkinson's disease and motor fluctuations: A

Roongroj Bhidayasiri, Michinori Koebis, Takanori Kamei, Takayuki Ishida, Ippei Suzuki, Jin Whan Cho, Shey-Lin Wu

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 4 countries.

Roongroj BhidayasiriChulalongkorn Centre of Excellence for Parkinson's Disease and Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
Michinori KoebisMedical Headquarters, Eisai Co., Ltd., Tokyo, Japan.
Takanori KameiMedical Headquarters, Eisai Co., Ltd., Tokyo, Japan.
Takayuki IshidaMedical Headquarters, Eisai Co., Ltd., Tokyo, Japan.
Ippei SuzukiClinical Evidence Generation Fulfillment, Deep Human Biology Learning, Eisai Co., Ltd., Tokyo, Japan.
Jin Whan ChoDepartment of Neurology, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Shey-Lin WuDepartment of Neurology, Changhua Christian Hospital, Changhua, Taiwan.
Eisai (Japan) · JPChanghua Christian Hospital · TWOffice of the Royal SocietySungkyunkwan University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Safinamide is a selective, reversible, monoamine oxidase B inhibitor for the treatment of patients with Parkinson's disease (PD) and motor fluctuations. This was a

Indexed as

levodopamonoamine oxidase B inhibitormotor fluctuationParkinson's diseasepost hoc analysissafinamidetreatment response

Identifiers

PMID37051060
PMCPMC10083404
OpenAlexW4360982718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.